白塞病患者中的嗜中性皮病与化脓性汗腺炎:自身炎症综合征谱系中的嗜中性疾病
在1462例白塞病患者中识别出20例(1.4%)合并嗜中性皮病或化脓性汗腺炎,其中13例为化脓性汗腺炎、6例为坏疽性脓皮病、1例为SAPHO综合征。坏疽性脓皮病在白塞病患者中似乎过代表,抗TNFα、乌司奴单抗和托珠单抗治疗难治性嗜中性皮病或化脓性汗腺炎似乎有前景。
要点
- 1462例白塞病患者中20例(1.4%)合并嗜中性皮病或化脓性汗腺炎。
- 6例坏疽性脓皮病对应患病率400/10万,提示在白塞病患者中过代表。
- 抗TNFα、乌司奴单抗和托珠单抗治疗难治性病例获得完全或部分缓解。
核心结论
- 坏疽性脓皮病在白塞病患者中似乎过代表。
- 抗TNFα、乌司奴单抗和托珠单抗等生物治疗用于治疗白塞病相关的难治性嗜中性皮病或化脓性汗腺炎似乎有前景。
研究设计与样本
- 从1462例白塞病患者中识别出20例合并嗜中性皮病或化脓性汗腺炎的患者。
主要发现
- 共分析20例(1.4%)诊断为白塞病相关嗜中性皮病或化脓性汗腺炎的患者:13例化脓性汗腺炎、6例坏疽性脓皮病、1例SAPHO综合征。
- 6例坏疽性脓皮病在1462例白塞病患者中对应患病率400/10万。
- 13例有双相口疮性口炎,6例有血管受累,5例有神经系统受累,4例有眼部受累。
- 所有坏疽性脓皮病均发生于四肢,具有典型组织学表现并伴持续性真皮嗜中性粒细胞浸润;所有化脓性汗腺炎均具有典型腋窝-乳腺表型,69%的化脓性汗腺炎为Hurley 1期。
- 治疗主要包括秋水仙碱(n=20)、糖皮质激素(n=12)和抗TNFα(n=9);抗TNFα(9例)、乌司奴单抗(3例)和托珠单抗(1例)治疗难治性白塞病相关嗜中性皮病或化脓性汗腺炎获得完全或部分缓解的有意义结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Association of neutrophilic dermatosis (ND), hidradenitis suppurativa (HS) and Behçet's disease (BD) and shared efficacy of TNFα axis blockade suggests common physiopathology. OBJECTIVES: To investigate the clinical features and therapeutic response of ND and HS associated with BD. METHODS: We identified 20 patients with ND or HS associated with BD among 1462 patients with BD. RESULTS: We analysed 20 (1.4%) patients diagnosed with ND or HS associated with BD: 13 HS, 6 pyoderma gangrenosum (PG), and 1 SAPHO. Our 6 PG cases over 1462 BD patients accounts for 400/100 000 prevalence. Thirteen had bipolar aphthosis, 6 vascular, 5 neurologic, and 4 ocular involvements. All PG occurred on limbs and had typical histology with constant dermal neutrophilic infiltrate. All HS had the classical axillary-mammary phenotype. Sixty-nine percent (69%) of HS were Hurley 1 stage. Treatment consisted mainly in colchicine (n = 20), glucocorticoids (n = 12), and anti-TNFα (n = 9). Interesting results with complete or partial responses were obtained with anti-TNFα (9 cases), ustekinumab (3 cases) and tocilizumab (1 case) to treat refractory ND or HS associated with BD. CONCLUSION: PG seems overrepresented in patients with BD. Biotherapies such as anti-TNFα, ustekinumab and tocilizumab appear to be promising to treat refractory ND or HS associated with BD.
引用
- Bugaut H, Barete S, Bagot M, et al. Neutrophilic dermatosis and hidradenitis suppurativa in patients with Behçet's disease: A neutrophilic disease in the spectrum of autoinflammatory syndromes. Semin Arthritis Rheum. 2023. PMID: 37207416. doi:10.1016/j.semarthrit.2023.152224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。